FDA Approves Selpercatinib for RET Fusion-Positive Thyroid Cancer

Thursday, 13 June 2024 | Solid Tumors

The FDA has approved selpercatinib for both adults and pediatric patients who are 2 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

To continue, please login or sign up first